Life Sciences BC Announces Incoming Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences BC (LSBC) is pleased to announce new and returning members to the Board of Directors, following its Annual General Meeting (AGM) held on September 15th, 2022. The incoming Board of Directors is comprised of leaders within British Columbia’s life sciences community, all of whom are aligned with LSBC’s vision and mission of creating a provincial ecosystem where life sciences and health organizations thrive, while advocating for and promoting the growth of the province’s world-class life sciences industry.

“We are thrilled to welcome our incoming Board of Directors for the upcoming year and thank those who are departing. The Life Sciences BC Board is made up of innovative leaders who share our passion for catalyzing the growth of our life sciences community in British Columbia and beyond. They generously volunteer their expertise, guidance and time to support LSBC and the ecosystem,” says Wendy Hurlburt, CEO and President of Life Sciences BC, and LSBC Board Member. “I am personally honoured to serve alongside some of the most talented and brilliant minds in our life sciences ecosystem and look forward to another exciting and productive year for BC’s life sciences.”

AGM Board Level Announcements

Suzanne Gill (Genome BC, President and CEO) and Bev Holmes (Michael Smith Health Research BC, President and CEO) were elected for three-year terms. Ian Heine (PWC, Partner) was elected for a one-year term.

Jennifer Cudlipp (LifeLabs Medical Laboratory, Chief Operating Officer), Michael Martin (Aurinia Pharmaceuticals, Chief Business Officer and Co-founder) and Anne Stevens (AbCellera, Vice President Business Development) were re-elected for three-year terms.

Joseph Garcia (Blakes, Partner), Hector MacKay-Dunn, K.C. (Farris, Senior Partner), and Roger Kuypers (Fasken, Partner) received renewed one-year appointments as Board Observers.

Rajveer Hundal (PwC, Partner) stepped down from LSBC’s Board, and Pascal Spothelfer (Past President and CEO of Genome BC) having completed two terms on the Board transitioned to a Board Observer.

At the Board Meeting following the AGM, Ali Ardakani (Novateur Ventures, Founder and Managing Director) became the new Chair of the Board of Directors. Scott Phillips (Starfish Medical, Founder and CEO) remains on the Board as Past Chair and Ian Heine became the Treasurer and Chair of the Finance Committee.

“As the incoming Chair of the LSBC Board of Directors, I am pleased to have the opportunity to represent such a dynamic leadership group,” says Ali Ardakani, Novateur Ventures Founder and Managing Director and incoming LSBC Board of Directors Chair. “Together, I look forward to raising even more awareness of our incredible life sciences hub in BC, further strengthening LSBC's mission of helping this ecosystem thrive while growing our presence and impact on the world stage.”

To see the full list of Life Sciences BC’s Board of Directors please visit: https://lifesciencesbc.ca/about-us/board-directors/

About Life Sciences BC 
Life Sciences BC is a not-for-profit, non-government association that supports and represents the life sciences community of British Columbia through leadership, facilitation of investment and partnering, and promotion of our world-class science and industry.

Life sciences sectors, from biopharmaceuticals and medical technology to digital health and medical devices, are integrated into our organization and all that we do, ensuring that no life sciences sector is working in isolation — and that all sectors come together in a comprehensive, complementary and coordinated fashion.

Throughout the year, Life Sciences BC undertakes numerous programs and projects in support of these sectors. These include public policy initiatives, facilitating linkages between global industry and our local organizations, raising the profile of our industry internationally and thus facilitating investment and global partnering opportunities, and helping nurture economic development in British Columbia through the life sciences industry.